Skip to content
Altius – Lifestyle
Author:
Nanoscope Therapeutics
Nanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment Conference
September 11, 2026
Nanoscope Therapeutics Announces U.S. Food and Drug Administration Acceptance of Biologics License Application for MOGENRY for the Treatment of Retinitis Pigmentosa with Severe Vision Loss
September 9, 2026
Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting
July 10, 2026
Catalent and Nanoscope Therapeutics Expand Partnership to Support Late-Phase Development and Commercial Supply of Lead Optogenetic Gene therapy, MCO-010
July 7, 2026
Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy
May 27, 2026
Nanoscope Therapeutics to Present Advanced Clinical and Manufacturing Findings at ASGCT 2026 Annual Meeting
May 11, 2026
←
Previous Page
1
2